Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK2295 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| MK2295 | DRUG | - |
Inclusion Criteria: * Patients in generally good health who are scheduled to have two or more third molars removed, at least one of which is partially or completely embedded in bone and is a mandibular impaction Exclusion Criteria: * Patient has a temperature of 37.5C or greater prior to dosing *...
MK2295 is an investigational small molecule being studied for the treatment of postoperative pain, specifically pain following tooth extraction. It was evaluated in a Phase 2 clinical trial for this indication. The drug is not approved and remains in clinical development.
MK2295 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company sponsored the clinical trial of this investigational drug for postoperative dental pain.
MK2295 is in Phase 2 clinical development. A Phase 2 trial evaluating the drug for postoperative dental pain has been completed. The drug is investigational and has not received regulatory approval for any use.
MK2295 has been studied in one completed Phase 2 clinical trial, registered as NCT00387140. This trial evaluated the safety and efficacy of the drug in 89 participants with postoperative dental pain following tooth extraction. The study was randomized and double-blind.
No alternative names for MK2295 have been identified. The drug is referred to solely as MK2295 in the available clinical trial information. It is an investigational small molecule being developed by Merck & Company, Inc.